# Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer

> **NCT02697058** · PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 84 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** BAX2398 + 5-FU/calcium levofolinate
- **DRUG:** 5-FU/calcium levofolinate

## Key facts

- **NCT ID:** NCT02697058
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-30
- **Primary completion:** 2017-05-04
- **Final completion:** 2018-08-28
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2024-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697058, "Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02697058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*